183 related articles for article (PubMed ID: 16207480)
1. Diffusion-weighted magnetic resonance imaging allows noninvasive in vivo monitoring of the effects of combretastatin a-4 phosphate after repeated administration.
Thoeny HC; De Keyzer F; Chen F; Vandecaveye V; Verbeken EK; Ahmed B; Sun X; Ni Y; Bosmans H; Hermans R; van Oosterom A; Marchal G; Landuyt W
Neoplasia; 2005 Aug; 7(8):779-87. PubMed ID: 16207480
[TBL] [Abstract][Full Text] [Related]
2. Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats.
Thoeny HC; De Keyzer F; Chen F; Ni Y; Landuyt W; Verbeken EK; Bosmans H; Marchal G; Hermans R
Radiology; 2005 Mar; 234(3):756-64. PubMed ID: 15734932
[TBL] [Abstract][Full Text] [Related]
3. Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging.
Thoeny HC; De Keyzer F; Vandecaveye V; Chen F; Sun X; Bosmans H; Hermans R; Verbeken EK; Boesch C; Marchal G; Landuyt W; Ni Y
Radiology; 2005 Nov; 237(2):492-9. PubMed ID: 16192323
[TBL] [Abstract][Full Text] [Related]
4. Comparison of two vascular-disrupting agents at a clinically relevant dose in rodent liver tumors with multiparametric magnetic resonance imaging biomarkers.
Wang H; Cona MM; Chen F; Yu J; Feng Y; Li J; Keyzer FD; Marchal G; Ni Y
Anticancer Drugs; 2012 Jan; 23(1):12-21. PubMed ID: 21857503
[TBL] [Abstract][Full Text] [Related]
5. Treatment of rodent liver tumor with combretastatin a4 phosphate: noninvasive therapeutic evaluation using multiparametric magnetic resonance imaging in correlation with microangiography and histology.
Wang H; Sun X; Chen F; De Keyzer F; Yu J; Landuyt W; Vandecaveye V; Peeters R; Bosmans H; Hermans R; Marchal G; Ni Y
Invest Radiol; 2009 Jan; 44(1):44-53. PubMed ID: 19034028
[TBL] [Abstract][Full Text] [Related]
6. Diffusion-weighted MRI of hepatic tumor in rats: comparison between in vivo and postmortem imaging acquisitions.
Sun X; Wang H; Chen F; De Keyzer F; Yu J; Jiang Y; Feng Y; Li J; Marchal G; Ni Y
J Magn Reson Imaging; 2009 Mar; 29(3):621-8. PubMed ID: 19243058
[TBL] [Abstract][Full Text] [Related]
7. Separate calculation of DW-MRI in assessing therapeutic effect in liver tumors in rats.
Chen F; De Keyzer F; Feng YB; Cona MM; Yu J; Marchal G; Oyen R; Ni YC
World J Gastroenterol; 2013 Dec; 19(47):9092-103. PubMed ID: 24379636
[TBL] [Abstract][Full Text] [Related]
8. In vivo near-infrared spectroscopy and magnetic resonance imaging monitoring of tumor response to combretastatin A-4-phosphate correlated with therapeutic outcome.
Zhao D; Chang CH; Kim JG; Liu H; Mason RP
Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):574-81. PubMed ID: 21345614
[TBL] [Abstract][Full Text] [Related]
9. Vascular targeting of solid tumours: a major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas.
Landuyt W; Verdoes O; Darius DO; Drijkoningen M; Nuyts S; Theys J; Stockx L; Wynendaele W; Fowler JF; Maleux G; Van den Bogaert W; Anné J; van Oosterom A; Lambin P
Eur J Cancer; 2000 Sep; 36(14):1833-43. PubMed ID: 10974632
[TBL] [Abstract][Full Text] [Related]
10. In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment.
Landuyt W; Ahmed B; Nuyts S; Theys J; Op de Beeck M; Rijnders A; Anné J; van Oosterom A; van den Bogaert W; Lambin P
Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):443-50. PubMed ID: 11173139
[TBL] [Abstract][Full Text] [Related]
11. Intra-individual comparison of therapeutic responses to vascular disrupting agent CA4P between rodent primary and secondary liver cancers.
Liu YW; De Keyzer F; Feng YB; Chen F; Song SL; Swinnen J; Bormans G; Oyen R; Huang G; Ni YC
World J Gastroenterol; 2018 Jul; 24(25):2710-2721. PubMed ID: 29991876
[TBL] [Abstract][Full Text] [Related]
12. Combretastatin A-4 and hyperthermia;a potent combination for the treatment of solid tumors.
Eikesdal HP; Bjerkvig R; Mella O; Dahl O
Radiother Oncol; 2001 Aug; 60(2):147-54. PubMed ID: 11439209
[TBL] [Abstract][Full Text] [Related]
13. Dynamic contrast-enhanced and diffusion-weighted MRI for early detection of tumoral changes in single-dose and fractionated radiotherapy: evaluation in a rat rhabdomyosarcoma model.
De Keyzer F; Vandecaveye V; Thoeny H; Chen F; Ni Y; Marchal G; Hermans R; Nuyts S; Landuyt W; Bosmans H
Eur Radiol; 2009 Nov; 19(11):2663-71. PubMed ID: 19504109
[TBL] [Abstract][Full Text] [Related]
14. Retrospective power analysis: when?
Erturk SM
Radiology; 2005 Nov; 237(2):743; author reply 743; discussion 743-4. PubMed ID: 16244281
[No Abstract] [Full Text] [Related]
15. Vascular targeting: a potential additional anti-cancer treatment.
Lambin P; Landuyt W
Verh K Acad Geneeskd Belg; 2003; 65(1):29-46. PubMed ID: 12802895
[TBL] [Abstract][Full Text] [Related]
16. Dynamic contrast-enhanced MRI in mouse tumors at 11.7 T: comparison of three contrast agents with different molecular weights to assess the early effects of combretastatin A4.
Fruytier AC; Magat J; Neveu MA; Karroum O; Bouzin C; Feron O; Jordan B; Cron GO; Gallez B
NMR Biomed; 2014 Nov; 27(11):1403-12. PubMed ID: 25323069
[TBL] [Abstract][Full Text] [Related]
17. Nitric oxide synthase inhibition enhances the tumor vascular-damaging effects of combretastatin a-4 3-o-phosphate at clinically relevant doses.
Tozer GM; Prise VE; Lewis G; Xie S; Wilson I; Hill SA
Clin Cancer Res; 2009 Jun; 15(11):3781-90. PubMed ID: 19470729
[TBL] [Abstract][Full Text] [Related]
18. Normal and transplanted rat kidneys: diffusion MR imaging at 7 T.
Yang D; Ye Q; Williams DS; Hitchens TK; Ho C
Radiology; 2004 Jun; 231(3):702-9. PubMed ID: 15163810
[TBL] [Abstract][Full Text] [Related]
19. Dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging noninvasive evaluation of vascular disrupting treatment on rabbit liver tumors.
Shao H; Ni Y; Zhang J; Chen F; Dai X; Fan G; Sun Z; Xu K
PLoS One; 2013; 8(12):e82649. PubMed ID: 24376560
[TBL] [Abstract][Full Text] [Related]
20. In vivo antitumour effect of combretastatin A-4 phosphate added to fractionated irradiation.
Ahmed B; Landuyt W; Griffioen AW; Van Oosterom A; Van den Bogaert W; Lambin P
Anticancer Res; 2006; 26(1A):307-10. PubMed ID: 16475711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
